The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Johnson & Johnson’s ...

Cardarine GW 501516 is a potent PPARβ and PPARδ receptor agonist. It is often misclassified as one of the known selective ...